June 2023
Volume 64, Issue 9
Open Access
ARVO Imaging in the Eye Conference Abstract  |   June 2023
SPECTRALIS TruTrack vs Next-Gen TruTrack for OCTA acquisitions: comparative quantitative assessment of agreement.
Author Affiliations & Notes
  • Michel Teussink
    Product Management and Clinical Affairs, Heidelberg Engineering GmbH, Heidelberg, Baden-Württemberg, Germany
  • Alessandro Arrigo
    Scientific Institute, Dept. Ophthalmology, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Maurizio Battaglia Parodi
    Scientific Institute, Dept. Ophthalmology, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Francesco Bandello
    Scientific Institute, Dept. Ophthalmology, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Footnotes
    Commercial Relationships   Michel Teussink, Heidelberg Engineering GmbH (E); Alessandro Arrigo, None; Maurizio Battaglia Parodi, None; Francesco Bandello, Alcon (C), Alimera Sciences (C), Allergan Inc (C), Bausch & Lomb (C), Bayer Shering-Pharma (C), Farmila-Thea (C), Genentech (C), Hoffmann-La-Roche (C), Novagali Pharma (C), Novartis (C), Pfizer (C), Sanofi-Aventis (C), Santen (C), Sifi (C), Thrombogenics (C), Zeiss (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, PB0099. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michel Teussink, Alessandro Arrigo, Maurizio Battaglia Parodi, Francesco Bandello; SPECTRALIS TruTrack vs Next-Gen TruTrack for OCTA acquisitions: comparative quantitative assessment of agreement.. Invest. Ophthalmol. Vis. Sci. 2023;64(9):PB0099.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Tracking of eye motion has a major impact on optical coherence tomography angiography (OCTA) image quality by, among other effects, reducing eye motion artifacts. We evaluated the performance of a newly implemented tracking approach, by comparing its resulting images and acquisition times with those of the commercially available tracking algorithm, for the Spectralis device.

Methods : We included 30 eyes (30 healthy subjects; 15 female; mean age 28±3) with clear media, no ocular diseases or surgery, and healthy systemic status. We collected the following OCTA acquisitions, by using Spectralis TruTrack (TT) and next-gen TruTrack (ngTT): macular high-resolution (HR) 85 kHz, high-speed (HS) 85 kHz, HR 125 kHz and HS 125 kHz (all ART 7; 15°x15°; Q-value >25) (Spectralis, Heidelberg Engineering, Germany). One blinded expert grader assessed intraretinal OCTA vascular slabs of co-registered OCTA volumes. The presence of artifacts was evaluated on a 3-point scale; 0 (no artifacts) to 1/ 2/ 3 (artifacts involving 1, 2, or ≥3 quadrants), as well as foveal avascular zone (FAZ) area, overall vessel density (VD) and sectorial VD analysis using a standardized 9-sector ETDRS grid. Agreements between continuous variables were analyzed by two-tailed T-tests. Tau-Kendall correlation analysis was also performed for the above variables and automatically logged OCTA acquisition times. P-values <0.05 were considered statistically significant.

Results : Compared to TT, ngTT OCTA acquisitions showed shortened acquisition times (p<0.05). FAZ area and overall VD values were comparable (p>0.05); however, by 9-sector ETDRS grid analysis we detected VD differences (p<0.05). TT showed higher prevalence of artifacts; these strongly correlated with the acquisition time (p<0.05). ngTT OCTA provided more consistent VD data than TT; on visual inspection the 85 kHz HR OCTA with ngTT provided the most detailed vascular reconstructions.

Conclusions : Probably due to improved patient compliance and reduced tear film degradation, ngTT outperformed TT in terms of artifact prevalence and microvascular visibility. Given that ngTT was specifically designed to address poor eye fixation combined with the encouraging data of the present study, ngTT would appear to substantially improve OCTA acquisition in patients with retinal disease: further study in that population is warranted.

This abstract was presented at the 2023 ARVO Imaging in the Eye Conference, held in New Orleans, LA, April 21-22, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×